{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:22:23Z","timestamp":1766157743467},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00482-014-1406-6","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T07:38:23Z","timestamp":1401953903000},"page":"289-293","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Schmerztherapie beim Reizdarmsyndrom"],"prefix":"10.1007","volume":"28","author":[{"given":"M.","family":"de Greck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Layer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"key":"1406_CR1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/gut.2006.100594","volume":"56","author":"Guilarte","year":"2007","unstructured":"Guilarte M, Santos J, Torres I de et\u00a0al (2007) Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56:203\u2013209","journal-title":"Gut"},{"key":"1406_CR2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.gastro.2003.11.055","volume":"126","author":"Barbara","year":"2004","unstructured":"Barbara G, Stanghellini V, De Giorgio R et\u00a0al (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126:693\u2013702","journal-title":"Gastroenterology"},{"key":"1406_CR3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2007.04.005","volume":"133","author":"Kassinen","year":"2007","unstructured":"Kassinen A, Krogius-Kurikka L, Makivuokko H et\u00a0al (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:24\u201333","journal-title":"Gastroenterology"},{"key":"1406_CR4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-230X-9-95","volume":"9","author":"Krogius-Kurikka","year":"2009","unstructured":"Krogius-Kurikka L, Lyra A, Malinen E et\u00a0al (2009) Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 9:95","journal-title":"BMC Gastroenterol"},{"key":"1406_CR5","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3748\/wjg.15.5936","volume":"15","author":"Lyra","year":"2009","unstructured":"Lyra A, Rinttila T, Nikkila J et\u00a0al (2009) Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15:5936\u20135945","journal-title":"World J Gastroenterol"},{"key":"1406_CR6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(00)70170-3","volume":"118","author":"Mertz","year":"2000","unstructured":"Mertz H, Morgan V, Tanner G et\u00a0al (2000) Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 118:842\u2013848","journal-title":"Gastroenterology"},{"key":"1406_CR7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2005.10.020","volume":"130","author":"Lawal","year":"2006","unstructured":"Lawal A, Kern M, Sidhu H et\u00a0al (2006) Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 130:26\u201333","journal-title":"Gastroenterology"},{"key":"1406_CR8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cgh.2008.02.060","volume":"6","author":"Camilleri","year":"2008","unstructured":"Camilleri M, McKinzie S, Busciglio I et\u00a0al (2008) Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6:772\u2013781","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1406_CR9","doi-asserted-by":"crossref","unstructured":"Layer P, Andresen V, Pehl C et\u00a0al (2011) Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z\u00a0Gastroenterol 49:237\u2013293","DOI":"10.1055\/s-0029-1245976"},{"key":"1406_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1542-3565(04)00124-7","volume":"2","author":"Costanza","year":"2004","unstructured":"Costanza CD, Longstreth GF, Liu AL (2004) Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol 2:395\u2013399","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1406_CR11","first-page":"CD005110","volume":"Rev","author":"Webb","year":"2007","unstructured":"Webb AN, Kukuruzovic RH, Catto-Smith AG et\u00a0al (2007) Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev:CD005110","journal-title":"Cochrane Database Syst"},{"key":"1406_CR12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ajg.2010.480","volume":"106","author":"Johannesson","year":"2011","unstructured":"Johannesson E, Simren M, Strid H et\u00a0al (2011) Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 106:915\u2013922","journal-title":"Am J Gastroenterol"},{"key":"1406_CR13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3748\/wjg.v20.i2.346","volume":"20","author":"Grundmann","year":"2014","unstructured":"Grundmann O, Yoon SL (2014) Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol 20:346\u2013362","journal-title":"World J Gastroenterol"},{"key":"1406_CR14","doi-asserted-by":"crossref","first-page":"a2313","DOI":"10.1136\/bmj.a2313","volume":"337","author":"Ford","year":"2008","unstructured":"Ford AC, Talley NJ, Spiegel BM et\u00a0al (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313","journal-title":"BMJ"},{"key":"1406_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gut.2008.167270","volume":"59","author":"Moayyedi","year":"2010","unstructured":"Moayyedi P, Ford AC, Talley NJ et\u00a0al (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325\u2013332","journal-title":"Gut"},{"key":"1406_CR16","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3748\/wjg.14.2650","volume":"14","author":"McFarland","year":"2008","unstructured":"McFarland LV, Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14:2650\u20132661","journal-title":"World J Gastroenterol"},{"key":"1406_CR17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.12460","volume":"38","author":"Hungin","year":"2013","unstructured":"Hungin AP, Mulligan C, Pot B et\u00a0al (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice \u2013 an evidence-based international guide. Aliment Pharmacol Ther 38:864\u2013886","journal-title":"Aliment Pharmacol Ther"},{"key":"1406_CR18","first-page":"CD004116","volume":"Rev","author":"Liu","year":"2006","unstructured":"Liu JP, Yang M, Liu YX et\u00a0al (2006) Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev:CD004116","journal-title":"Cochrane Database Syst"},{"key":"1406_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(94)91055-3","volume":"344","author":"Francis","year":"1994","unstructured":"Francis CY, Whorwell PJ (1994) Bran and irritable bowel syndrome: time for reappraisal. Lancet 344:39\u201340","journal-title":"Lancet"},{"key":"1406_CR20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2013.08.017","volume":"145","author":"Castro","year":"2013","unstructured":"Castro J, Harrington AM, Hughes PA et\u00a0al (2013) Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3\u2019,5\u2019-monophosphate. Gastroenterology 145:1334\u20131346.e1\u201311","journal-title":"Gastroenterology"},{"key":"1406_CR21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","volume":"107","author":"Chey","year":"2012","unstructured":"Chey WD, Lembo AJ, Lavins BJ et\u00a0al (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702\u20131712","journal-title":"Am J Gastroenterol"},{"key":"1406_CR22","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","volume":"107","author":"Rao","year":"2012","unstructured":"Rao S, Lembo AJ, Shiff SJ et\u00a0al (2012) A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107:1714\u20131724","journal-title":"Am J Gastroenterol"},{"key":"1406_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/apt.12123","volume":"37","author":"Quigley","year":"2013","unstructured":"Quigley EM, Tack J, Chey WD et\u00a0al (2013) Randomised clinical trials: linaclotide phase\u00a03 studies in IBS-C \u2013 a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 37:49\u201361","journal-title":"Aliment Pharmacol Ther"},{"key":"1406_CR24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.cgh.2013.04.032","volume":"11","author":"Videlock","year":"2013","unstructured":"Videlock EJ, Cheng V, Cremonini F (2013) Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 11:1084\u20131092.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1406_CR25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/apt.12604","volume":"39","author":"Layer","year":"2014","unstructured":"Layer P, Stanghellini V (2014) Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 39:371\u2013384","journal-title":"Aliment Pharmacol Ther"},{"key":"1406_CR26","first-page":"CD003460","volume":"Rev","author":"Quartero","year":"2005","unstructured":"Quartero AO, Meineche-Schmidt V, Muris J et\u00a0al (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev:CD003460","journal-title":"Cochrane Database Syst"},{"key":"1406_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/gut.2008.163162","volume":"58","author":"Ford","year":"2009","unstructured":"Ford AC, Talley NJ, Schoenfeld PS et\u00a0al (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58:367\u2013378","journal-title":"Gut"},{"key":"1406_CR28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","volume":"6","author":"Andresen","year":"2008","unstructured":"Andresen V, Montori VM, Keller J et\u00a0al (2008) Effects of 5-hydroxytryptamine (serotonin) type\u00a03 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 6:545\u2013555","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1406_CR29","doi-asserted-by":"crossref","unstructured":"Pimentel M, Lembo A, Chey WD et\u00a0al (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N\u00a0Engl J Med 364:22\u201332","DOI":"10.1056\/NEJMoa1004409"},{"key":"1406_CR30","first-page":"488","volume":"108","author":"Schafer","year":"1990","unstructured":"Schafer E, Ewe K (1990) The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon. Fortschr Med 108:488\u2013492","journal-title":"Fortschr Med"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-014-1406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-014-1406-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-014-1406-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:28:10Z","timestamp":1559093290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-014-1406-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1007\/s00482-014-1406-6","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}